1 / 12

Non-Small Cell Lung Cancer Genetic Predictors

Non-Small Cell Lung Cancer Genetic Predictors. Sacha Rothschild, MD PhD Medical Oncology. The genomic evolution of lung adenocarcinoma. Pao et al. Lancet Oncol 2011; Pao and Hutchinson. Nat Med 2012.

euclid
Télécharger la présentation

Non-Small Cell Lung Cancer Genetic Predictors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Non-Small Cell Lung CancerGenetic Predictors Sacha Rothschild, MD PhD Medical Oncology

  2. The genomicevolutionoflungadenocarcinoma Pao et al. Lancet Oncol 2011; Pao and Hutchinson. Nat Med 2012 NSCLC Symposium St. Gallen - Genetic Predictors

  3. Survival of patients with oncogenic drivers – targeted therapy vs. no targeted therapy Kris et al. Abstract PL03-07 NSCLC Symposium St. Gallen - Genetic Predictors

  4. Mutations in the EGFR tyrosine kinase domain Pao W, et al. PNAS 2004; Paez J, et al. Science 2004 NSCLC Symposium St. Gallen - Genetic Predictors

  5. EGFR-TKIs vs. Chemotherapy as first-line therapy 7 randomizedtrialsconfirmingtheroleoffirst-line EGFR-TKI in patientswith EGFR-mutatedadenocarcinoma 1Mok et al. NEJM 2009; 2Lee et al. WCLC 2009; 3Mitsudomi et al. Lancet Oncol 2010; 4Maemondo et al. NEJM 2010; 5Zhou et al. ESMO 2010; 6Rosell et al. Lancet Oncol 2012; 7Yang et al. ASCO 2012; abstract LBA7500 NSCLC Symposium St. Gallen - Genetic Predictors

  6. Mechanismsof Resistance to EGFR kinaseinhibitors in EGFR mutant NSCLC Yu HA, et al. Clin Cancer Res 2013;19:2240-7 NSCLC Symposium St. Gallen - Genetic Predictors

  7. EML4-ALK translocations in NSCLC • EML4-ALK frequency: ~ 4% • Primarily in adenocarcinoma • More common in younger patients • More common in never-smokers Soda M et al. Nature 2007; 448:561-566.Koivunen et al. CCR 2008 NSCLC Symposium St. Gallen - Genetic Predictors

  8. PROFILE 1007 – PFS by independent radiologic review Median PFS: 7.7 vs. 3.0 months Shaw AT, et al. NEJM 2013;368:2385-94 NSCLC Symposium St. Gallen - Genetic Predictors

  9. ALK-inhibitor resistance mechanisms in ALK-positive NSCLC Doebele RC, et al. ClinCancer Res 2012;18:1472-82; Shaw AT, et al. ASCO 2013; abstract 8010 NSCLC Symposium St. Gallen - Genetic Predictors

  10. ROS1 • Receptortyrosinekinaseoftheinsulinreceptorfamily • 1-2% oflungadenocarcinomaspecimensharbor ROS1 fusionabnormality • More common in never-smokersand Asian patients • ROS1 fusionwiththetransmembranesolutecarrierprotein SLC34A2 results in a constitutivekinaseactivity in a NSCLC cellline Rikova, et al. Cell 2007; Takeuchi, et a. Nat Med 2011; Bergethon, et al. JCO 2012; Oxnard et al. J ClinOncol 2013 NSCLC Symposium St. Gallen - Genetic Predictors

  11. Crizotinib in ROS1 positive NSCLC – a phase II study Ou et al. Abstract O16.07 NSCLC Symposium St. Gallen - Genetic Predictors

  12. RAS signallingnetworks Kamauband Weinberg, Nat Rev 2008 NSCLC Symposium St. Gallen - Genetic Predictors

More Related